The Psychedelic on the Fringes of Medicine
- Sheila Thompson, RN CPHQ
- 15 hours ago
- 6 min read
Despite surprising new advocates in Republican lawmakers and conservative veterans’ groups, ibogaine remains controversial as a treatment for serious mental illness and substance use disorder.
An Executive Order issued April 18, 2026, seeks to “accelerate innovative research models and appropriate drug approvals to increase access to psychedelic drugs that could save lives and reverse the crisis of serious mental illness in America”. It directs the FDA and DEA to establish pathways under the Right to Try Act for eligible patients to access psychedelics, including ibogaine, and directs the Department of Health and Human Services (HHS) to allocate $50 million to State governments that are advancing these drugs for the treatment of serious mental illness (SMI). It also promotes collaboration and data-sharing between HHS, the FDA, and the Department of Veterans Affairs (VA).
Texas was quick to jump on the bandwagon, announcing in March 2026 that the state would proceed with publicly funded research after failing to secure a private sector option- an unusually aggressive example of state involvement in psychedelic medicine. Veterans Exploring Treatment Solutions (VETS), a non-profit advocacy organization, has been a strong supporter of the Texas Ibogaine Initiative.
What is Ibogaine and How Does it Work?
Ibogaine is derived from the roots of a shrub native to Central Africa called Tabernanthe iboga, used in traditional Bwiti spiritual ceremonies for centuries. The French marketed it as a stimulant called Lambarène in the early part of the 20th century, but it was an American heroin addict who claimed in the 1970s to have experienced complete withdrawal and a sudden and lasting end to heroin cravings after just one dose of ibogaine. Similar stories and some preclinical study findings sparked scientists’ curiosity about its potential for use in psychiatric disorders, including substance use disorder (SUD).
Psychedelics that have been considered for SUD treatment fall into two categories: classic and non-classic. Ibogaine belongs to the non-classic group, which also includes ketamine and MDMA. These are thought to act on opioid system and serotonin receptors and may affect the reward systems that fuel addiction by decreasing dopamine levels. Substances in the classic psychedelic category act as serotonin receptor agonists, affecting cognitive function and mood, and include psilocybin, mescaline, and lysergic acid diethylamide (LSD).
Because ibogaine acts on multiple receptors in the brain, it has the potential to treat traumatic brain injury (TBI), SUD, depression, and post-traumatic stress disorder (PTSD).
Ibogaine typically causes vivid dreams and hallucinations, beginning within a few hours of administration and lasting up to 24 hours. The effects occur in 3 phases: visionary, introspection, and residual.
Why Researchers Are Revisiting Ibogaine Now
SMI (such as major depression, bipolar disorder, and schizophrenia) and the SUDs that often accompanies these conditions, are increasingly a global health concern, causing death, disability, and financial stress. Researchers estimate that 4-7% of adults experience SMI worldwide with a projected 10 to 20-year decrease in life expectancy due to resulting health risks and suicide. The global economic impact is projected to hit $16 trillion by 2030. Data from 2023 reported an estimated 61.5 million people globally using opioids, an increase of more than 7 million in just 4 years, and approximately 600,000 deaths annually. Co-occurring SUD leads to more resistance to treatment, increased incarceration and hospitalization rates, and greater suicide risk. Unfortunately, especially in low- to middle-income countries, these individuals rarely receive any mental health treatment. Approved treatments in the US include the opioid substitutes methadone and buprenorphine and the opioid antagonist naltrexone, but long-term adherence is poor, leading to high relapse rates. It’s clear that this crisis warrants new accessible, effective approaches for SMI and SUD treatment.
Veterans and their advocacy groups are changing the conversation by connecting psychedelics to suicide prevention in the aftermath of military trauma and demanding federal research support for treatment of PTSD, TBI, and comorbid SUD. By reducing the counterculture stigma, veterans add legitimacy to the shift in political stance regarding psychedelics among the Republican majority. High profile voices including President Donald Trump, HHS Secretary Robert F. Kennedy Jr, podcaster Joe Rogan, former Secretary of Energy Rick Perry, and Texas Governor Greg Abbott are reversing decades of American drug policy.
Why is it Controversial?
Those who support the use of ibogaine point to patient testimonials and reports of dramatically reduced withdrawal symptoms. A study published in 2017 included 88 participants who were recruited from a detox treatment center in Mexico, most of whom had been treated for heroin or prescription opioid abuse. Participants responded to survey questions about their perception of treatment effectiveness, how treatment with ibogaine compared to other treatment modalities, and post-treatment cravings, mood, and psychological well-being. Key reported findings include:
More than half (54%) remained abstinent for at least 1 year and 30% never resumed opioid use after treatment. Those that relapsed reported decreased opioid usage.
Half the respondents experienced reduced opioid craving of at least a week and 25% reported craving reduction lasting at least 3 months.
71% felt that treatment with ibogaine was “much better” than other treatments and 85% said they would have made the same decision regarding ibogaine treatment based on their experience.
43% reported improvement in mood or well-being for at least a month, and 10% noted improvement in mood for 5 months or more.
Overall, 61% of study participants rated ibogaine treatment as “very effective”.
While encouraging, the limitations of this and other studies include the use of small sample sizes and subjective or observational data. A comprehensive literature review published in 2025 revealed few placebo-controlled or double-blind studies and a high risk of bias across most studies, further compounded by weak study design and lack of comparable methodology.
Ibogaine is classified as a Schedule 1 drug in the United States, making it difficult to study and illegal to use, though there are illicit ibogaine treatment options with accompanying safety and legal issues. Thousands seeking treatment travel to clinics in countries where ibogaine’s legality varies or is ambiguous, such as Mexico, Canada, Brazil, the Netherlands, South Africa, and New Zealand. These clinics differ greatly in quality, and treatment programs lack standardized protocols.
The drug’s complex properties and mechanism of action earned that classification, thus limiting its safe use in the clinical setting. Dosing is complicated due to active metabolites and a long half-life, and the risk of toxicity increases with pre-existing conditions, concomitant drug use, and inadequate medical supervision. Serious side effects include neurotoxicity at high does, sudden cardiac death, and fatal arrhythmias linked to prolonged QT intervals on EKG.
The Future of Ibogaine
While ibogaine and its primary metabolite noribogaine have demonstrated anecdotal success in treating SMI and SUD, the lack of adequate clinical trials and the risks of adverse cardiac outcomes and neurotoxicity give scientists and clinicians pause. The latest research is exploring certain iboga alkaloids known as oxa-iboga that have shown greater efficacy in animal models with less of ibogaine’s adverse effects. By slightly altering the chemical structure of ibogaine, researchers demonstrated decreased withdrawal symptoms, drug-seeking, and relapse, and most notably, mitigated cardiotoxicity in rodents. In another approach, 18MC is a synthetic iboga analog that has shown efficacy similar to ibogaine and noribogaine in rodent preclinical assays, but further studies are needed to determine whether oxa-iboga versions will be superior in SUD treatment. Numerous other compounds are in various stages of development and testing, as the narrative shifts from “does iboga work?” to “can we make it safe?”
What Would Success Look Like?
There is no question that the global opioid epidemic has reached epic proportions, escalating the urgency to develop better treatments for SMI and SUD. We must use caution however, so the hype around ibogaine doesn’t outrun the evidence. While funding and support for research is beneficial, many researchers remain focused on adequate clinical trials with consistently replicable results and the exploration of safer analogues with lower cardiac risk. If successful, it could mean revolutionizing addiction treatment, redefining medical approaches to trauma and compulsive behaviors, and even expanding the science of psychedelic medicine.
At present, ibogaine remains teetering on the edge of breakthrough versus gamble, with unresolved tension between desperate need and scientific rigor, where the outcome may depend as much on politics and public pressure as on science.
Resources
Executive Order April 18, 2026
“Texas will launch its own clinical trials into ibogaine psychedelic after failing to find a drug company to help”
“Veterans Exploring Treatment Solutions (VETS) Leads Legislative Day of Action on March 18, 2025 in Support of Texas Ibogaine Initiative”
“Reconsidering Ibogaine for the treatment of severe mental illness and substance use disorders”
“Ibogaine: Therapeutic Potential, Cardiac Safety, and Translational Perspectives in the Treatment of Substance Use Disorders—A Scoping Review” (2026)
“Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning”
“The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies”
“Oxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models” (2024)
Published in Nature Communications.
“Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies” (2025)
“The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients” (2024)
“A transcriptomic analysis in mice following a single dose of ibogaine identifies new potential therapeutic targets” (2024)
Assessed and Endorsed by the MedReport Medical Review Board